目的 通过研究鸟分枝杆菌复合群对氯法齐明、贝达喹啉和德拉马尼的药物敏感性，初步评估其对鸟分枝杆菌复合群肺病治疗的价值。方法 采用微孔板 Alamar Blue 法测定氯法齐明、贝达喹啉和德拉马尼对 12 株鸟分枝杆菌临床分离株和 81 株胞内分枝杆菌临床分离株的最低抑菌浓度（MIC）， 使用相关软件计算 MIC50、MIG90和流行病学界值（ECOFF）。结果 氯法齐明对胞内分枝杆菌的 MIC50和 MIC90分别为 0.25 μg/mL 和 0.5 μg/mL，ECOFF 值为 0.5 μg/mL；贝达喹啉对胞内分枝杆菌的 MIC50和 MIC90分 别为 0.125 μg/mL 和 0.25 μg/mL，ECOFF 值为 0.25 μg/mL；德拉马尼对 97.5%（79/81）胞内分枝杆菌的MIC ≥ 256 μg/mL。氯法齐明对鸟分枝杆菌的MIC50和MIC90分别为0.25 μg/mL 和 0.5 μg/mL，ECOFF 值为 0.5 μg/mL； 贝达喹啉对 75%（9/12）的鸟分枝杆菌的 MIC 均为 0.062 5 μg/mL；德拉马尼对 91.7%（11/12）的鸟分枝杆菌 的 MIC 均为> 4 μg/mL。结论 氯法齐明、贝达喹啉对鸟分枝杆菌复合群有较好的体外抑菌活性，德拉马 尼对鸟分枝杆菌复合群无明显抑菌作用。

Objective To investigate the susceptibility of Mycobacterium avium complex to clofazimine， bedaquiline and delamanid，and therefore to explore the possibility of using these drugs to treat Mycobacterium avium complex lung disease. Methods The minimum inhibitory concentrations（MICs）of clofazimine，bedaquiline，and delamanid against 12 M. avium clinical isolates and 81 M. intracellulare clinical isolates were determined by using the microplate alamar blue assay（MABA）. Results The MIC50 and MIC90 of clofazimine against M. intracellulare were 0.25 μg/mL and 0.5 μg/mL，respectively. ECOFF of clofazimine against M. intracellulare was 0.5 μg/mL. The MIC50 and MIC90 of bedaquiline against M. intracellulare were 0.125 μg/mL and 0.25 μg/mL，respectively. ECOFF of bedaquiline against M. intracellulare was 0.25 μg/mL. The MICs of delamanid against 97.5%（79/81）of M. intra⁃ cellulare clinical isolates were ≥ 256 μg/mL. The MIC50 and MIC90 of clofazimine against M. avium were 0.25 μg/mL and 0.5 μg/mL，respectively. ECOFF of clofazimine against M. avium was 0.5 μg/mL. The MICs of bedaquiline against 75%（9/12）of M. avium clinical isolates were 0.0625 μg/mL；and the MICs of delamanid against 91.7% （11/12）of M. avium clinical isolates were > 4 μg/mL. Conclusions Clofazimine and bedaquiline showed acceptable in vitro activity against M. avium complex，and Delamanid has no effect on M. avium complex.